MoFo News Item

MoFo Advises Immune-Onc in $73 Million Financing

31 Mar 2021

Morrison & Foerster advised Immune-Onc Therapeutics, Inc. in a $73 million follow-on to its previous Series B financing. The round was led by Oceanpine Capital with participation from additional new investors, including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.

Based in Palo Alto, California, Immune-Onc is a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints. Proceeds from the financing will allow Immune-Onc to advance its portfolio of blood cancer and solid tumor immunotherapies targeting myeloid checkpoints with a focus on the LILRB family.

The MoFo deal team was led by John Campbell, senior counsel in the firm’s Emerging Companies + Venture Capital Group in San Francisco, with assistance from Charles Comey, a partner focused on investment transactions between China and the United States, and associates Jim Ryan and Ophir Gam, all based in Palo Alto.

For further information on the company and transaction, see the press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.